The Filing Desk

Embecta

EMBC · Nasdaq · Health Care · Financials, fiscal 2020 to 2025

EMBC · Last close · November 19, 2026
$6.19
Value Embecta yourself

Embecta's revenue fell 3.8% to $1.1 billion in fiscal 2025. Its operating margin was 22.4%, up from 14.8% a year earlier. Free cash flow was $182 million, up 816.6%. It paid out $35 million in dividends and buybacks, 19% of free cash flow. The diluted share count rose 1.0%.

EMBECTA CORP. Latest fiscal year ended September 30, 2025 10-K filed November 25, 2025 · 0001872789-25-000036 Updated
Revenue
$1.1B
3.8%
Operating margin
22.4%
7.6 pts
Net income
$95M
21.8%
Free cash flow
$182M
816.6%
Return on capital
29.3%
1.2 pts
Market cap
$362M
Nov 19 close
P/E
4.2x
On $1.47 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Embecta does

Embecta makes and sells devices for people with diabetes who inject insulin. Its products include pen needles, which attach to pen injectors that deliver insulin or other diabetes medicines, as well as syringes and safety injection devices. Its safety pen needles have shields that cover the needle after the injection to help prevent needlestick injuries.

It sells through pharmacies, wholesalers and other customers, and it says a substantial part of its revenue comes from a few of them. It competes with other makers of injection devices and with providers of insulin pumps. It separated from Becton, Dickinson and Company in 2022 and still buys the cannulas, the thin tubes in its needles, from that company.

Its fiscal year ends September 30. At the end of fiscal 2025 it had about 1,850 regular employees worldwide, with about 700 of them in the United States.

Its biggest risks, as it describes them

  • A few key products produce much of its profits and cash flow.
  • Advances in diabetes treatment or prevention could reduce demand for its products.
  • A few customers account for a substantial part of its revenue.
  • Problems in manufacturing or sterilizing its products could hurt its business.
From Embecta's annual report on Form 10-K, filed November 25, 2025, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2020 to 2025, earnings per share fell 26.4% a year and net income 25.9% a year, as new shares raised the share count by 3% and diluted each share's earnings.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments0331326268226
Debt incl. finance leases01,6441,6381,6081,430
Net debt (negative means net cash)01,3131,3121,3411,205
Net debt to EBITDA0.0x3.9x5.2x6.6x4.3x
Debt to equity0.0x————
Interest coverage—8.0x2.0x1.4x2.3x
Current ratio1.8x2.2x2.1x2.0x2.4x
Quick ratio1.1x1.8x1.7x1.6x1.7x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Embecta's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 4 insiders bought $557,850 of Embecta shares on the open market, and 1 insider sold $37,003.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 4, 2026Milton Mayo MorrisDirectorSold6,293$5.88$37,003Form 4
Aug 12, 2026Robert J. HombachDirectorBought45,000$4.97$223,650Form 4
Aug 12, 2026Devdatt KurdikarPresident and CEO, DirectorBought30,000$4.70$141,000Form 4
Aug 12, 2026Jeffrey Z MannPres, Pharm Svc&Prod Mgmt, CLOBought20,000$4.99$99,800Form 4
Aug 12, 2026Jacob ElguiczeSVP and CFOBought20,000$4.67$93,400Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 93 of 96 of 9
Rule of 402.9%2.0%13.1%
Altman Z''1.491.201.99
Accruals ratio0.2%3.4%−8.1%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positivePassPassPass
Cash from operations is positivePassPassPass
Return on assets roseFailFailPass
Cash from operations exceeds net incomeFailFailPass
Debt fell relative to assetsPassPassPass
Current ratio roseFailFailPass
Share count didn't riseFailFailFail
Gross margin roseFailFailFail
Revenue rose relative to assetsFailFailFail
F-score3 of 93 of 96 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Embecta side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
EmbectaFY25−3.8%22.4%16.9%29.3%4.3x6
Tandem Diabetes CareFY257.9%−18.4%−2.9%−85.5%—4Compare
Stevanato Group S.p.A.FY257.5%16.8%1.9%8.3%—6Compare
Inspire Medical SystemsFY2513.6%5.6%8.6%14.2%−4.8x5Compare
CONMEDFY255.2%7.5%11.0%3.7%5.1x6Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

6 years of figures

Fiscal yearFY20FY21FY22FY23FY24FY25
Income statement
Revenue1,0861,1651,1301,1211,1231,080
Revenue growth—7.3%−3.1%−0.8%0.2%−3.8%
Gross profit763800775750735677
Research and development616367857937
Operating income486492310222167242
Net income428415224707895
Diluted EPS (US$)7.507.283.891.221.341.62
Diluted shares (millions)575758585859
Cash flow
Cash from operations4984564126836192
Capital expenditure42372426169
Free cash flow4574203894120182
Dividends paid009343435
Share buybacks000000
Acquisitions000000
Stock-based compensation131319222632
Balance sheet at fiscal year end
Cash and short-term investments00331326268226
Debt incl. finance leases—01,6441,6381,6081,430
Total assets—7881,0861,2141,2851,091
Total liabilities—1941,9782,0362,0241,742
Shareholders' equity572594−891−822−738−651
Margins and ratios
Gross margin70.2%68.7%68.6%66.9%65.5%62.6%
Operating margin44.8%42.2%27.4%19.8%14.8%22.4%
Net margin39.4%35.6%19.8%6.3%7.0%8.8%
Free cash flow margin42.1%36.0%34.4%3.7%1.8%16.9%
Rule of 40 (growth + FCF margin)—43.4%31.3%2.9%2.0%13.1%
Return on capital——53.1%32.4%30.5%29.3%
Return on equity——————
Return on assets——23.9%6.1%6.3%8.0%
Net debt to EBITDA—0.0x3.9x5.2x6.6x4.3x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Embecta's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Embecta.